Skip to main content
Premium Trial:

Request an Annual Quote

Bruker AXS IPO Sells 9 Million Shares for $53 Million

NEW YORK, Dec. 14 — X-ray system developer Bruker AXS earned $53 million after filing an initial public offering on Friday that let loose 9 million shares of common stock at a cost of $6.50 apiece, the company announced on Friday. Shares of the Madison, Wis.-based firm began trading on the Nasdaq on Friday under the ticker symbol BAXS, trading at $6.75 just after 11:00 a.m.

 

The company said it plans to use the proceeds for general purposes, including R&D, expanding sales and marketing, strategic acquisitions, general expansion, and debt repayment.

 

The two main underwriters were UBS Warburg and Thomas Weisel Partners. CIBC World Markets, SG Cowen, and Robert W. Baird & Co. were co-managers.

 

Bruker AXS develops and sells advanced systems for crystallography, X-ray diffraction, and X-ray fluorescence. It has development partnerships with GeneFormatics and an equity stake in Integrative Proteomics, and acquired the X-ray crystallography division of Delft Instruments in March. 

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.